4.8 Article

Bariatric Surgery and Prevention of Type 2 Diabetes in Swedish Obese Subjects

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 367, 期 8, 页码 695-704

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1112082

关键词

-

资金

  1. AstraZeneca
  2. New York Obesity Nutrition Research Center
  3. Pathway Genomics
  4. Weight Watchers
  5. Nike
  6. Human Kinetics and Informa Healthcare
  7. Pfizer
  8. Roche
  9. Novartis
  10. Johnson Johnson
  11. Swedish Research Council [K2012-55X-22082-01-3, K2010-55X-11285-13, K2008-65x-20753-01-4]
  12. Swedish Foundation for Strategic Research
  13. Swedish federal government under the LUA/ALF
  14. VINNOVA-VINNMER program
  15. Wenner-Gren Foundations
  16. Hoffmann-La Roche
  17. Cederroth
  18. Sanofi-Aventis

向作者/读者索取更多资源

BACKGROUND Weight loss protects against type 2 diabetes but is hard to maintain with behavioral modification alone. In an analysis of data from a nonrandomized, prospective, controlled study, we examined the effects of bariatric surgery on the prevention of type 2 diabetes. METHODS In this analysis, we included 1658 patients who underwent bariatric surgery and 1771 obese matched controls (with matching performed on a group, rather than individual, level). None of the participants had diabetes at baseline. Patients in the bariatric-surgery cohort underwent banding (19%), vertical banded gastroplasty (69%), or gastric bypass (12%); nonrandomized, matched, prospective controls received usual care. Participants were 37 to 60 years of age, and the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) was 34 or more in men and 38 or more in women. This analysis focused on the rate of incident type 2 diabetes, which was a prespecified secondary end point in the main study. At the time of this analysis (January 1, 2012), participants had been followed for up to 15 years. Despite matching, some baseline characteristics differed significantly between the groups; the baseline body weight was higher and risk factors were more pronounced in the bariatric-surgery group than in the control group. At 15 years, 36.2% of the original participants had dropped out of the study, and 30.9% had not yet reached the time for their 15-year follow-up examination. RESULTS During the follow-up period, type 2 diabetes developed in 392 participants in the control group and in 110 in the bariatric-surgery group, corresponding to incidence rates of 28.4 cases per 1000 person-years and 6.8 cases per 1000 person-years, respectively (adjusted hazard ratio with bariatric surgery, 0.17; 95% confidence interval, 0.13 to 0.21; P< 0.001). The effect of bariatric surgery was influenced by the presence or absence of impaired fasting glucose (P = 0.002 for the interaction) but not by BMI (P = 0.54). Sensitivity analyses, including end-point imputations, did not change the overall conclusions. The postoperative mortality was 0.2%, and 2.8% of patients who underwent bariatric surgery required reoperation within 90 days owing to complications. CONCLUSIONS Bariatric surgery appears to be markedly more efficient than usual care in the prevention of type 2 diabetes in obese persons. (Funded by the Swedish Research Council and others; ClinicalTrials.gov number, NCT01479452.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据